Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vitro Kinetic Characterization of Axitinib Metabolism.

Drug metabolism and disposition: the biological fate of chemicals - 1 Jan 2016

Zientek Michael A, Goosen Theunis C, Tseng Elaine, Lin Jian, Bauman Jonathan N, Walker Gregory S, Kang Ping, Jiang Ying, Freiwald Sascha, Neul David, Smith Bill J

Abstract excerpt

N-Methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide (axitinib) is an oral inhibitor of vascular endothelial growth factor receptors 1-3, which is approved for the treatment of advanced renal cell cancer. Human [(14)C]-labeled clinical studies indicate axitinib's primary route of clearance is metabolism. The aims of the in vitro experiments presented herein were to identify and characterize...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Cytochrome P-450 CYP1A2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 Enzyme Inhibitors

Share to Glucuronides

Share to Inactivation, Metabolic

Share to Indazoles

Share to Metabolic Clearance Rate

Share to Microsomes, Liver

Source

Identifiers

PMID: 26512042
DOI: 10.1124/dmd.115.065615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vitro Kinetic Characterization of Axitinib Metabolism.PMID 26512042Read ↗

Population pharmacokinetic analysis of axitinib in healthy volunteers.Semantic proximity Read ↗

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.Semantic proximity Read ↗

Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.Semantic proximity Read ↗

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.Semantic proximity Read ↗

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.Semantic proximity Read ↗

Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.Semantic proximity Read ↗

Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes.Semantic proximity Read ↗

Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.Semantic proximity Read ↗

Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5.Semantic proximity Read ↗

Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats.Semantic proximity Read ↗

Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitor.Semantic proximity Read ↗

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.